RegenXBio (RGNX)

RegenXBio (RGNX) Financial Statements


RegenXBio Financial Overview

RegenXBio's market cap is currently ―. The company's EPS TTM is $-5.877; its P/E ratio is -1.98; RegenXBio is scheduled to report earnings on August 7, 2024, and the estimated EPS forecast is $-1.29. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Sep 23Jun 23Mar 23Dec 22
Income Statement-
Total Revenue$ 22.21M$ 28.91M$ 19.98M$ 19.14M$ 31.34M
Gross Profit$ 10.97M$ 16.53M$ 10.53M$ 14.99M$ 25.94M
EBIT$ -61.68M$ -60.24M$ -70.94M$ -66.16M$ -57.77M
EBITDA$ -57.34M$ -56.01M$ -66.13M$ -61.30M$ -70.67M
Net Income Common Stockholders$ -62.89M$ -61.43M$ -72.06M$ -66.68M$ -59.94M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 275.26M$ 301.89M$ 320.08M$ 331.82M$ 364.64M
Total Assets$ 573.97M$ 633.79M$ 682.46M$ 747.83M$ 691.58M
Total Debt$ 89.29M$ 90.70M$ 91.58M$ 93.30M$ 94.80M
Net Debt$ -185.97M$ -211.19M$ -228.50M$ -238.52M$ -269.84M
Total Liabilities$ 262.23M$ 270.69M$ 276.60M$ 282.69M$ 833.22M
Stockholders Equity$ 311.74M$ 363.10M$ 405.85M$ 465.14M$ 516.15M
Cash Flow-
Free Cash Flow$ -41.89M$ -50.85M$ -49.90M$ -85.74M$ -44.85M
Operating Cash Flow$ -40.76M$ -49.41M$ -47.32M$ -80.92M$ -39.38M
Investing Cash Flow$ 33.97M$ 38.66M$ 55.22M$ 63.09M$ 26.70M
Financing Cash Flow$ -11.96M$ -4.80M$ -9.16M$ -9.04M$ -8.92M
Currency in USD

RegenXBio Earnings and Revenue History

RegenXBio Debt to Assets

RegenXBio Cash Flow

RegenXBio Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis